March 28th 2025
The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.